Kanker payudara merupakan salah satu masalah kesehatan prioritas baik di skala global maupun nasionaL. Kunci utama penanganan kanker payudara terletak pada deteksi dini dan tata laksana yang komprehensif khususnya dengan mengkaji faktor prognostik yang mempengaruhi luaran klinisnya. Pertambahan ukuran tumor primer dan metastasis memiliki prognosis buruk. Progresi tumor dan metastasis berkaitan erat dengan proses angiogenesis. Vascular Endothelial Growth Factor(VEGF) merupakan faktor proangiogenesis penting dalam proses angiogenesis. Penelitian VEGF serum pada kanker payudara masih menunjukkan hasil yang tidak konsisten. Saat ini belum ada penelitian yang secara khusus menilai korelasi kadar VEGF serum dengan ukuran tumor pada pasien kanker payudara di RSUP Dr. Sardjito. Penelitian ini secara khusus bertujuan untuk menilai korelasi kadar VEGF serum dengan ukuran tumor primer pada kanker payudara. Subjek penelitian adalah penderita kanker payudara operableyang berkunjung ke poliklinik kanker terpadu Tulip dan di Ruang Perawatan Bedah RSUP Dr. Sardjito. Data penelitian bersumber dari hasil wawancara melalui kuesioner, berkas rekam medis dan pemeriksaan sampel di instalasi laboratorium klinik RSUP Dr. Sardjito. Normalitas data dinilai dengan uji Saphiro Wilk, uji beda rerata kadar VEGF serum pada berbagai stadium dengan Independent t-test atau Mann-Whitneydan One way Annova test, sedangkan korelasi kadar VEFG serum dengan ukuran tumor primer dilakukan dengan uji korelasi Spearman. Penelitian ini melibatkan 40 pasien kanker payudara operable. Hasil penelitian ini menunjukkan bahwa median VEGF serum adalah 541,53 (96,87 – 1413,48) pg/mL. Rerata kadar VEGF pada kanker payudara stadium IB adalah 132,29 (±50,18)pg/mL, stadium IIA adalah 541,09 (±315,03) pg/mL, stadium IIB adalah 582,5 (±296,27) pg/mL,stadium IIIA 713,70 (±432,05)pg/mL, dan stadium IIIB adalah 900,90 (±724,90)pg/mL.Tidak terdapat perbedaan bermakna rerata kadar VEGF serum berdasarkan stadium klinis kanker payudara. Berdasarkan ukuran tumor klinisT1, T2, dan T3 dan kejadian metastasis limfonodi, juga tidak didapatkan perbedaan bermakna rerata kadar VEGF serum antara kelompok tersebut. Terdapat korelasi positif sedang antara kadar VEGF serum dengan ukuran tumor primer pada kanker payudara, dengan r=0,46 dan p=0,03. Kata kunci: kanker payudara, ukuran tumor, angiogenesis, Vascular Endothelial Growth Factor, serum

Breast canceris among the priorityhealthproblems, globally and nationally. Key success of breast cancer treatment depends on early detectionandcomprehensive clinical management, especially by using appropriateprognostic factorsaffectingclinicaloutcomes. Metastasisand the increase of primary tumor size is related with poor prognosis. Tumor progressionandmetastasisis closely related tothe process ofangiogenesis.Vascular Endothelial Growth Factor (VEGF) is a proangiogenesis factor that plays important role in the angiogenesis process. However, various studies concerning the roles of VEGF in breast cancer showed inconsistent results. Until currently, in Sardjito Teaching Hospital, no particular study was conducted to assess the correlation of serum VEGF levels with tumor size in breast cancer patients. This study specifically aims to assess the correlation of VEGF serum levels with the size of the primary tumor in breast cancer. Subjects wereoperable breast cancer patients who visited the Oncology Tulip clinic and underwent treatment at the ward. Data were collected from various sources including interviews with questionnaires, medical record file and results of sample examination. Data normality was assessed withSaphiro Wilk test. Accordingly, mean differences of VEGF serum levels between groups were assessed with Independent-ttest or Mann Whitney and One way Annova test. To obtain the correlation between VEGF serum levels with tumor size, Spearman correlation has been applied. The study included 40 patients with operable breast cancer. The results of this study showed that the median of VEGF serum was 541.53 (96.87 to 1413.48) pg/mL. VEGF serum meanof breast cancer subjects with stage IBwas 132.29 (± 50.18) pg/mL, stage IIA was 541.09 (± 315.03) pg / ml, stage IIB was 582.5 (± 296.27) pg/mL, stage IIIA 713.70 (± 432.05) pg/mL, and stage IIIB was 900.90 (± 724.90) pg/mL. There weremean differences of VEGF serum levels based on the clinical stage of breast cancer. No mean differences of VEGF serum were found between subjects withtumor size of T1, T2, and T3 and those with and without lymph node metastasis. However, there was a positive correlation between serum VEGF levels with the size of the primary tumor in breast cancer, with r = 0.46 and p = 0.03. Key words : breast cancer, tumor size, angiogenesis, Vascular EndothelialGrowth Factor, serum

Kata Kunci : kanker payudara, ukuran tumor, angiogenesis, Vascular Endothelial Growth Factor, serum